In vivo comparison of CHX-DTPA ligand isomers in athymic mice bearing carcinoma xenografts

Cancer Biotherapy and Radiopharmaceuticals

Volumn 14, Issue 3, 1999, Pages 209-220

  Roselli, Mario ^a,b   Milenic, Diane E ^a   Brechbiel, Martin W ^a   Mirzadeh, Saed ^a,c   Pippin, C Greg ^a   Gansow, Otto A ^a   Colcher, David ^a,d   Schlom, Jeffrey ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c OAK RIDGE NATIONAL LABORATORY   (United States)

^d UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Chelates; Indium; Monoclonal antibody; Radioimmunotherapy; Yttrium

Indexed keywords

CHELATING AGENT; INDIUM; MONOCLONAL ANTIBODY; PENTETIC ACID; YTTRIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHELATION; COLON CARCINOMA; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG STABILITY; DRUG UPTAKE; FEMALE; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; ISOMER; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; TUMOR LOCALIZATION; XENOGRAFT;

EID: 0033062769     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.1999.14.209     Document Type: Article

References (49)

1. Larson SM. Clinical radioimmunodetection, 1978-1988: Overview and suggestions for standardization of clinical trials. Cancer Res 1990;50:892s.
2. Sands H. Experimental Studies of radioimmunodetection of cancer, An overview. Cancer Res 1990;50:809s.
3. O'Brien HA, Jr, Radioimmunoimaging and radioimmunotherapy, Burchiel SW and Rhodes BA, ed., Elsevier, New York, 1983:161.
4. Roselli M, Schlom J, Gansow OA, Raubitschek A, Mirzadeh S, Brechbiel MW and Colcher D. Comparative biodistributions of yttrium- and indium-labeled monoclonal antibody B72.3 in athymic mice bearing human colon carcinoma xenografts. J Nucl Med 1989;30:672.
5. Camera L, Kinuya S, Garmestani K, Wu C, Brechbiel MW, Pia LH, McMurray TJ, Gansow OA, Pastan I, Paik CH and Carrasquillo JA. Evaluation of the serum stability and in vivo biodistribution of CHX-DTPA and other ligands for yttrium labeling of monoclonal antibodies. J Nucl Med 1994;35:882.
6. DeNardo SJ, Richman CM, Goldstein DS, Shen S, Slako Q, Kukis DL, Meares, CF, Yuan A, Welborn JL and DeNardo GL. Yttrium-90/indium-111-DOTA-peptide-chimeric L6: Pharmacokinetics, dosimetry and initial results in patients with incurable breast cancer. Anticancer Res 1997;17:1735.
7. DeNardo SJ, Kramer EL, O'Donnell RT, Richman CM, Salako QA, Shen S, Noz M, Glenn SD, Ceriani RL and DeNardo GL. Radioimmunotherapy for breast cancer using indium-111/yttrium-90 BrE-3: Results of a phase I clinical trial. J Nucl Med 1997;38:1180.
8. 90Y Mx-diethylenetriaminepentaacetic acid (DTPA)-BrE-3 and autologous hematopoietic stem cell support (AHSCS) for the treatment of advanced breast cancer. Cancer Res 1995;55:5921s.
9. Leichner PK, Akabami G, Colcher D, Harrsion KA, Hawkins WG, Eckblade M, Baranowska-Kortylewicz J, Augustine SC, Wisecarver J and Tempero MA. Patient-specific dosimetry of indium-111- and yttrium-90-labeled monclonal antibody CC49. J Nucl Med 1997;38:512.
10. Vriesendorp HM, Morton JD and Quadri SM. Review of five consecutive studies of radiolabeled immunoglobulin therapy in Hodgkin's disease. Cancer Res 1995; 55: 5888s.
11. 90Yittrium-radiolabeled anti-carcinoembryonic antigen chimeric T84.66 in a phase I radioimmunotherapy trial. Cancer Res 1995; 55: 5959s.
12. 90Y-CYT-356 monoclonal antibody. Clin Cancer Res 1996;2:1289.
13. Waldmann TA, White JD, Carrasquillo JA, Reynolds JC, Paik CH, Gansow OA, Brechbiel MW, Jaffe ES, Fleisher TA, Goldman CK, Top LE, Bamford R, Zaknoen S, Roessler E, Kasten-Sportes C, England R, Litou H, Johnson JA, Jackson-White T, Manns A, Hanchard B, Junghans RP and Nelson DL. Radioimmunotherapy of interleukin-2Rα-expressing adult T-cell leukemia with yttrium-90-labeld anti-Tac. Blood 1995;86:4063.
14. Kozak RB, Raubitschek A, Mirzadeh S, Brechbiel MW, Junghans R, Gansow OA, Waldmann T. Nature of the bifunctional chelating agent used for radioimmunotherapy with yttrium-90 monoclonal antibodies, critical factors in determining in vivo survival and organ toxicity. Cancer Res 1989;49:2639.
15. Esteban JM, Schlom J, Gansow OA, Atcher RW, Brechbiel MW, Simpson DE and Colcher D. New method for the chelation of indium-111 to monoclonal antibodies: biodistribution and imaging of athymic mice bearing human colon carcinoma xenografts. J Nucl Med 1987;28: 861.
16. Brechbiel MW, Gansow OA, Atcher RW, Schlom J, Esteban J, Simpson D and Colcher D. Synthesis of 1-(p-isothiocyanatobenzyl) derivatives of DTPA and EDTA. Antibody labeling and tumor imaging studies. Inorg Chem 1986;25:2772.
17. Jowsey J, Rowland RE and Marshall JH. The deposition of the rare earths in bone. Radiation Res 1958;8: 490.
18. 90Y-labeled monoclonal antibodies as a third line of treatment in ovarian cancer. A phase 1-2 trial: problems encountered and possible solutions. Br J Cancer 1990;10(suppl):48.
19. Maraveyas A, Snook D, Hird V, Kosmas C, Meares CF, Lambert HE and Epenetos AA. Pharmacokinetics and toxicity of an yttrium-90-CITC-DTPA-HMFG1 radioimmunoconjugate for intraperitoneal radioimmunotherapy of ovarian cancer. Cancer 1994;73:1067.
20. Hnatowich DJ, Chinol M, Siebecker DA, Gionet M, Griffin T, Doherty PW, Hunter R and Kase KR. Patient biodistribution of intraperitoneally administered yttrium-90-labeled antibody. J Nucl Med 1988;29:1428.
21. 90Y-labeled monoclonal antidoes for ovarian cancer: pharmacokinetics and normal tissue dosimetry. Int J Cancer 1988;3(suppl.):71.
22. Stewart JSW, Hird V, Snook D, Dhokia B, Coulter C, Lambert HE, Mason WP, Soutter WP and Epenetos AA. Intraperitoneal yttrium-90-labeled monoclonal antibody in ovarian cander J Clin Oncol 1990;8:19441.
23. Meares CF, McCall MJ, Reardan DT, Goodwin DA, Diamanti CI and McTigue M. Conjugation of antibodies with bifunctional chelating agents: Isothiocyanate and bromoacetamide reagents, methods of analysis, and subsequent addition of metal ions. Anal Biochem 1984;142:68.
24. Roselli M, Schlom J, Gansow OA, Brechbiel MW, Mirzadeh S, Pippin CG, Milenic DE and Colcher D. Comparative biodistribution studies of DTPA-derivative bifunctional chelates for radiometal labeled monoclonal antibodies Nucl Med Biol 1991;4:389.
25. Brechbiel MW and Gansow OA, Synthesis of C-functionalized trans-cyclohexyldiethylenetriaminepentaacetic acids for labelling of monoclonal antibodies with the bismuth-212 α-particle emitter. J Chem Soc, Perkin Trans 1992;1:173.
26. Colcher D, Esteban JM, Carrasquillo JA, Sugarbaker P, Reynolds JC, Bryant G, Larson SM and Schlom J. Quantitative analyses of selective radiolabeled monoclonal antibody localization in metastatic lesions of colorectal cancer patients. Cancer Res 1987;47:1185.
27. Nieroda CA, Mojzisik C, Sardi A, Farrar WB, Hinkle G, Siddiqi MA, Ferrara PJ, James A, Schlom J, Thurston MO and Martin EW, Jr. Staging of carcinoma of the breast using a hand-held gamma detecting probe and monoclonal antibody B72.3. Surgery, Gynecology and Obstetrics 1989;169:35.
28. 131I-B72.3. Int J Rad Appl Instrum [B] 1989;16:127.
29. Maguire RT and Van Nostrand D. Diagnosis of Colorectal and Ovarian Carcinoma: Application of Immunoscintigraphic Technology. Marcel Dekker, Inc., New York, 1992.
30. Renda A, Salvatore M, Sava M, Landi R, Lastoria S, Coppola L, Schlom J, Colcher D and Zannini G. Immunoscintigraphy in the follow-up of patients operated on for carcinoma of the sigmoid and rectum. Preliminary report with a new monoclonal antibody B72.3. Dis Colon and Rectum 1987;30:683.
31. Carrasquillo JA, Sugarbaker P, Colcher D, Reynolds JC, Esteban J, Bryant G, Keenan AM, Perentesis P, Yokoyama K, Simpson DE, Ferroni P, Farkas R, Schlom J and Larson SM Radioimmunoscintigraphy of colon cancer with I-131-labeled B72.3 monoclonal antibody. J Nuc Med 1988;29:1022.
32. Schlom J, Milenic DE, Siler K, Yokota T, Kashmiri SVS and Horan Hand P. Cancer Therapy in the Twenty-First Century Vol I: Molecular & Immunologic Approaches, Huber BE (ed), Futura Publishing Co., Inc., Mount Kisco, 1994:181.
33. 212Bi for α-particle mediated radioimmunotherapy. J Chem Soc, Chem Commun, 1991;17:1169.
34. Colcher D, Horan Hand P, Nuti M and Schlom J. A spectrum of monoclonal antibodies reactive with human mammary tumor cells. Proc Natl Acad Sci USA 1981;78:3199.
35. Colcher D, Keenan AM, Larson SM, Schlom J. Prolonged binding of a radiolabeled monoclonal antibody (B72.3) used for the in situ radioimmunodetection of human colon carcinoma xenografts. Cancer Res 1984;44:5744.
36. Mirzadeh S, Brechbiel MW, Atcher RA and Gansow OA. Radiometal labeling of immunoproteins: covalent linkage of 2-(4-isothiocyanatobenzyl)diethylenetriaminepentaacetic acid ligands to immunoglobulin. Bioconjugate Chem 1990;1:59.
37. Fraker PJ and Speck JC. Protein and cell membrane iodinations with a sparingly soluble chloramide 1,3,4,6-terachloro-3α,6α-diph
38. Colcher D, Minelli FM, Roselli M, Muraro R, Simpson-Milenic D and Schlom J. Radioimmunolocalization of human carcinoma xenografls with B72.3 second generation monoclonal antibodies. Cancer Res 1988;48: 4597.
39. Tom BH, Rutzky LP and Jakstys MM. Human colonic adenocarcinoma cells. I. Establishment and description of a new line. In Vitro 1976;12:180.
40. Schott ME, Milenic DE, Yokota T, Whitlow M, Wood JF, Fordyce WA, Cheng RA, and Schlom J. Differential metabolic patterns of iodinated versus radiometal chelated anticarcinoma single-chain Fv molecules. Cancer Res 1992;52:6413.
41. 111 complexes. J Org Chem 1993;58:1955.
42. Kosmas C, Snook D, Gooden CS, Courtney-Luck NS, McCall MJ, Meares CF and Epenetos AA. Development of humoral immune responses against a macrocyclic chelating agent (DOTA) in cancer patients receiving radioimmunoconjugates for imaging and therapy. Cancer Res 1992;52:904.
43. Kosmas C, Maraveyas A, Gooden CS, Snook D and Epenetos AA. Anti-chelate antibodies after intraperitoneal yttrium-90-labeled monoclonal antibody immunoconjugates for ovarian cancer therapy. J Nucl Med 1995;36:746.
44. Watanabe N, Goodwin DA, Meares CF, McTigue M, Chaovapong W, Ransone CM and Renn O. Immunogenicity in rabbits and mice of an antibody-chelate conjugate: comparison of (S) and (R) macrocyclic enantiomers and an acyclic chelating agent. Cancer Res 1994;54: 1049.
45. 111In-labeled B3 monoclonal antibody: Biodistribution and imaging studies in nude mice bearing human epidermoid carcinoma xenografts. Cancer Res 1993;53:2834.
46. 111In-labeled B3 monoclonal antibody in athymic mice bearing human epidermoid carcinoma xenografts. Nucl Med Biol 1993;20:955.
47. 212Bi-anti-Tac. Cancer Res 1994;54:4362.
48. Yokota T, Milenic DE, Whitlow M and Schlom J. Rapid tumor penetrance of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 1992;52:3402.
49. Slavin-Chiorini DC, Kashmiri SVS, Schlom J, Calvo B, Shu LM, Schott ME, Milenic DE, Snoy P, Carrasquillo J, Anderson K and Horan Hand P. Biological properties of chimeric domain-deleted anticarcinoma immunoglobulins. Cancer Res 1995;55:5957s.